semaglutide patient information Cardiovascular Disease Semaglutide and Type 2 Diabetes
Description
Dietary needs change by decade
Many therapy areas had high growth in days of therapy in 2023 led by GLP-1 agonists driving obesity and diabetes. As the bar chart clearly tells us from the 3rd line on the bottom of the graph, obesity leads the top 30 therapy areas by growth from 2022
A comprehensive program could make weight loss treatments a worthy investment for organizations
It is used alone or with other medications toimprove blood glucose (sugar) levels for people with Type 2 Diabetes
